Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 10-K, Date: 2013-04-15, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: BSPM/20130415/10-K_1/1/000.htm SEC Original: biostar10k123112.htm
FORM 10-K (Mark One) x December 31, 2012 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former

---

---

Webplus: BSPM/20130415/10-K_1/2_EX-10.7/000.htm SEC Original: ex10-7.htm
Product Research and Development Agreement Party A: Shaanxi Aoxing Pharmaceutical Co. Ltd. Party B: Life Science Academy of Northwest University Party A and Party B reached the following R&D agreement regarding National Type I new medicine Danshensu Borneol Ester through friendly negotiation: 2. Project research progress: (1) Party B has finished the research of DBZ’s activity, technical, quality standard and

---

---

Webplus: BSPM/20130415/10-K_1/3_EX-23.1/000.htm SEC Original: ex23-1.htm
Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (No. 333-161598) and S-8 (No. 333-183387) of Biostar Pharmaceuticals, Inc. of our report dated April 11, 2013 relating to the consolidated financial statements, which appears in the Annual Report

---

---

Webplus: BSPM/20130415/10-K_1/4_EX-23.2/000.htm SEC Original: ex23-2.htm
CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Mazars CPA Limited Certified Public Accountants Hong Kong April 11, 2013 EX-23.2 4 ex23-2.htm

---

---

Webplus: BSPM/20130415/10-K_1/5_EX-31.1/000.htm SEC Original: ex31-1.htm
CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period

---

---

Webplus: BSPM/20130415/10-K_1/6_EX-31.2/000.htm SEC Original: ex31-2.htm
CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period

---

---

Webplus: BSPM/20130415/10-K_1/7_EX-32.1/000.htm SEC Original: ex32-1.htm
CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm

---

---

Webplus: BSPM/20130415/10-K_1/8_EX-32.2/000.htm SEC Original: ex32-2.htm
CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 8 ex32-2.htm

---

Company Information:

Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 10-K, Date: 2013-04-15, XBRL Interactive FinancialsCIK: 0001418133, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE 712046